

WHAT IS CLAIMED IS:

1. An isolated or purified peptide comprising an Isoleucyl-valyl-threonyl-asparaginyL-threonyl-threonine peptide.
2. An isolated or purified peptide according to Claim 1 consisting essentially of an Isoleucyl-valyl-threonyl-asparaginyL-threonyl-threonine peptide.
3. The peptide of Claim 2 wherein said peptide reduces the symptoms of a viral disease.
4. The peptide of Claim 3, wherein said viral disease is hepatitis B infection.
5. The peptide of Claim 1, wherein said peptide has immuno-stimulating properties.
6. A peptide according to any of the Claims 1-5 wherein said peptide is L-Isoleucyl-L-valyl-L-threonyl-L-asparaginyL-L-threonyl-L-threonine.
7. A peptide according to any of the Claims 1-5 wherein said peptide is in a substantially pure form.
8. A pharmaceutical composition comprising an Isoleucyl-valyl-threonyl-asparaginyL-threonyl-threonine peptide.
9. A pharmaceutical composition according to Claim 8 comprising a L-Isoleucyl-L-valyl-L-threonyl-L-asparaginyL-L-threonyl-L-threonine.
10. A method of making a pharmaceutical composition comprising providing an Isoleucyl-valyl-threonyl-asparaginyL-threonyl-threonine peptide and mixing said peptide with a pharmaceutically acceptable carrier.
11. A method of reducing the effects of a human disease comprising administering a pharmaceutically effective dose of an Isoleucyl-valyl-threonyl-asparaginyL-threonyl-threonine peptide.
12. The method of Claim 11, wherein said human suffers from a viral disease.
13. The method of Claim 12, wherein said viral disease is hepatitis B infection.
14. A method of stimulating the immune system of an individual comprising administering a pharmaceutically effective dose of an Isoleucyl-valyl-threonyl-asparaginyL-threonyl-threonine peptide.
15. The use of an Isoleucyl-valyl-threonyl-asparaginyL-threonyl-threonine peptide as a pharmaceutical compound.

16. The use according to Claim 15 wherein said compound is used for treating a viral disease.

17. The use according to Claim 16, wherein said viral disease is hepatitis B infection.

18. The use of an Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine peptide as an immune stimulant.

19. The use of an Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine peptide as a nutritional supplement.

20. A molecule comprising an enhanced derivative of Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine peptide, said enhanced derivative comprising an enhancement molecule operably linked to said Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine peptide, said enhancement molecule enhancing the therapeutic effectiveness of said peptide.